Pretreatment lymphocyte‐to‐monocyte ratios predict AIDS‐related diffuse large B‐cell lymphoma overall survival

Abstract

The lymphocyte‐to‐monocyte ratio (LMR) and platelet‐to‐lymphocyte ratio (PLR) have been reported to be useful for predicting the prognosis of various malignancies, including diffuse large B‐cell lymphoma (DLBCL). However, little is known about the role of LMR and PLR in the prognosis of DLBCL patients with human immunodeficiency virus (HIV) infection. We retrospectively evaluated the prognostic value of the LMR and PLR in patients with newly diagnosed AIDS‐related diffuse large B‐cell lymphoma (AR‐DLBCL) who were treated with CHOP‐like chemotherapy at a single institution. In 33 AR‐DLBCL patients, the median follow‐up period was 32 months (range: 7–85 months), with an estimated 2‐year overall survival (OS) rate of 79.9%. The univariate analysis confirmed the LMR ≤ 2.74 (p = .015), PLR ≥ 337.7 (p = .019), and moderate anemia (p = .045) were associated with inferior survival. The independent significant association between low LMR and poor OS in the multivariate analysis was identified (HR: 0.033, 95% CI: 0.001–0.853, p = .040). However, PLR (p = .459) and moderate anemia (p = .102) did not retain an independent significance in the multivariate analysis. Moreover, compared with the high‐LMR group, patients with low‐LMR more frequently had B symptoms (p = .010) and lower CD4+T cell count (p < .001). The pretreatment LMR may be an effective prognostic factor for predicting OS in patients with AR‐DLBCL.

Clinical Characteristics and Prognostic Factors of HIV-Positive Patients With Lymphoma in the Poverty Region of China: A Real-World Multicenter Analysis

“…Fortunately, this situation has improved since 2018, and 39.3% of AIDS-defining DLBCL patients receive curative-intent treatment with six to eight cycles of CHOP-or EPOCH-based strategies. In fact, the latest 2-year OS and PFS rates were 62.7%-79.9% and 56.4%-64% in high-income regions of China, such as Beijing, Shanghai, and Nanjing [8,10,12]. All this underscores the necessity to improve the standard hierarchical management and supportive care of HIV/AIDS-associated lymphomas in low-income and middle-income regions of China.…”

“…HIV/AIDs occurs frequently in the southwestern region (e.g., Guangxi, Yunnan, Guizhou, Sichuan, and Chongqing), the northwestern region of Xinjiang, and in a central province of Henan [7]. In the last decade, a few region-specific, population-level studies have sporadically described the epidemiological features, clinical characteristics, pathobiology, management, or prognosis of HIV-associated lymphomas in China [8][9][10][11][12]. The outcomes of Chinese ARL patients have improved in recent years, especially in high-income regions.…”

Preoperative Biomarkers and Survival in Chinese Breast Cancer Patients with HIV: A Propensity-Score-Matched-Cohort Study

“…Comparable lymphocyte-to-monocyte ratio cut-off values have been identified in previous studies carried out on patients with HIV. For instance, Zeng et al [ 37 ] highlighted a strong association between a diminished lymphocyte-to-monocyte ratio (<2.74) and unsatisfactory survival outcomes in individuals with diffuse large B-cell lymphoma. Of course, a sophisticated randomized controlled trial would be necessary to lend weight to these results.…”

Clinical Features, Phenotypic Markers and Outcomes of Diffuse Large B-Cell Lymphoma between HIV-Infected and HIV-Uninfected Chinese Patients

“…Currently, the data on HIV-infected Chinese DLBCL patients are uncomprehensive. Some studies illustrated well the basic clinical characteristics of HIV-related DLBCL based on a small Chinese population [ 19 , 20 , 21 ]. Thus, a further study is necessary to enrich the data of HIV-infected Chinese DLBCL patients.…”